Condition: Metastatic Breast Cancer · Triple Negative Breast Cancer · Estrogen-receptor-low Breast Cancer · Sponsor: Kathy Miller
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
This description comes directly from the study's public registry record.
Xin Bryan, RN · 317-274-5495 · zhongx@iupui.edu
Always discuss trial participation with your own doctor first.
| Emory University | Atlanta, Georgia, United States | Recruiting |
| IU Health Joe and Shelly Schwarz Cancer Center | Carmel, Indiana, United States | Recruiting |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| Sidney and Lois Eskenazi Hospital | Indianapolis, Indiana, United States | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05846789